

为患者而生

For patients, for life.



公司概况 SIMCERE PREVIEW

先声药业 (2096.HK) 是一家创新与研发驱动的制药公司。公司聚焦神经科学、抗肿瘤、自身免疫及抗感染领域，同时积极前瞻性布局未来有重大临床需求的疾病领域，履行“为患者而生”的企业使命。公司以自主研发及协同创新双轮驱动，与多家创新型企业、科研院校建立战略合作伙伴关系。

Sincere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We focus on the therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore the areas with significant clinical needs, and our mission is "For patients, for life."

Our industry-leading capabilities and commitment to synergistic innovation have enabled various strategic collaborations and we are seen as the partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and the world.

对外技术授权 OUT-LICENSING

累计对外授权5项，总金额超46亿美金。

Out-licensing Achievements: 5 Deals with a Total Value Exceeding USD 4.6 Billion.

融合蛋白SIM0278 (IL-2 mu-Fc)



- 自免创新项目 IL-2 专利技术成功许可给欧洲药企Almirall
- 首付款加里程碑付款总额**5.07亿美元**
- 中美II期临床进行中

· Innovative portfolio for autoimmune disorders licensed to a European biopharma Almirall.
· Potential transaction value up to \$507 million.
· Phase II clinical trial is currently ongoing in China & U.S.

皮下三特异性抗体SIM0500 (GPCR5D/BCMA/CD3)



- 治疗多发性骨髓瘤的创新分子专利授权给全球第三大制药企业
- 首付款以及最高**10.55亿美元**选择性权益和里程碑付款
- 中美I期临床研究进行中，**全球开发进度处于第一梯队**

· Option to license agreement with Abbvie.
· Option fees and milestone payments up to \$1.055 billion.
· Phase I clinical trial is currently ongoing in China& the U.S, maintaining first-tier global development progress.

ADC新药SIM0505 (CDH6 ADC)



- 治疗实体瘤的CDH6靶点新药海外权益授权给NextCure
- 首付款加里程碑付款总额**7.45亿美元**
- 中美I期临床研究进行中

· Overseas rights to a novel CDH6-targeted drug for the treatment of solid tumors have been licensed to Nextcure.
· A total deal value up to \$745 million comprising an upfront payment and milestone payments.
· Phase I clinical trial is currently ongoing in China& the U.S.

ADC新药SIM0613 (LRRC15 ADC)



- 治疗实体瘤的LRRC15 ADC靶点新药海外权益授权给Ipsen
- 首付款加里程碑付款总额**10.6亿美元**
- 已在中国获批进入临床研究

· Overseas rights to a novel LRRC15-targeted drug for the treatment of solid tumors have been licensed to Ipsen.
· A total deal value up to \$1060 million comprising an upfront payment and milestone payments.
· Obtained IND approval in China.

双抗新药SIM0709 (TL1A/IL23p19)



- 治疗炎症性肠病的TL1A/IL23p19双抗海外权益授权给Boehringer Ingelheim
- 首付款加里程碑付款总额**10.58亿欧元**
- 在IBD治疗领域具有“同类首创”潜力

· Built a licensing partnership with Boehringer Ingelheim, a TL1A/IL23p19 bispecific antibody to address unmet needs inflammatory bowel disease.
· Total payments up to EUR 1058 million.
· Best-in-class potential for IBD treatment.